PREVALENCA TRADICIONALNIH KARDIOVASKULARNIH FAKTORA RIZIKA ZA KORONARNU ARTERIJSKU BOLEST I POVIŠENOG FIBRINOGENA MEDJU AKTIVNIM VOJNIM LICIMA VOJSKE REPUBLIKE SRBIJE: STUDIJA PRESEKA

Tradicionalni kardiovaskularni faktori fizika i povišen fibrinogen medju aktivnim vojnim licima vojske Srbije

  • Milena Slobodan Pandrc Military Medical Academy
  • Nenad Ratković
  • Vitomir Perić
  • Maja Stojanović
  • Vanja Kostovski
  • Nemanja Rančić
Ključne reči: tradicionalni kardiovaskularni faktori rizika, koronarna arterijska bolest, fibrinogen, aktivna vojna lica

Sažetak


Uvod: Dobro je poznato da manje od 1% populacije postiže idealno kardiovaskularno zdravlje, kao i da 65% pacijenata nema konvencionalne biomarkere rizika pod kontrolom. Vojna služba ima svoje osobitosti koje mogu doprineti kardiovaskularnom riziku.

Metod: Da bismo definisali ciljeve preventivne strategije, analizirali smo prevalenciju tradicionalnih kardiovaskularnih faktora rizika za koronarnu arterijsku bolest i povišenog fibrinogena među aktivnim vojnim licima vojske Republike Srbije.

Rezultati: Studija preseka obuhvatila je 738 osoba starijih od 20 godina, uglavnom između 31 i 40 godina. Srednja vrednost SBP -a za celu grupu bila je 122.39 ± 9.42 mmHg, a za DBP 79.94 ± 6.56 mmHg. Među ispitivanom populacijom 72.7% (533), imalo je prehipertenziju, a 13.8% (101) hipertenziju. Utvrđeno je da se i telesna masa i indeks telesne mase među posmatranim starosnim podgrupama povećavaju sa godinama pacijenata, kao i vrednosti ukupnog holesterola. Vrednosti HDL holesterola takođe su se statistički značajno razlikovale među starosnim podgrupama, pri čemu je udeo pojedinaca sa HDL-om manjim od 1,5 mmol / L u svim podgrupama bio oko 85%, dok je jedino u starosnoj grupi od 41-50 godina bio niži, 76,4%. LDL holesterol, kao i udeo pojedinaca koji su imali LDL ≥3,5, raste sa starenjem pacijenata, a identičan trend je zabeležen i kod triglicerida. Sa starenjem, nivo fibrinogena se povećava.

Zaključci: Dobijeni rezultati koji se odnose na kardio i cerebrovaskularne faktore rizika bi mogli doprineti stvaranju novog pristupa u primarnoj prevenciji u ovih kategorija bolesnika.  

Reference

1. Simic R, Ratkovic N, Dragojevic Simic V, Savkovic Z, Jakovljevic M, Peric V, Pandrc M, Rancic N. Cost Analysis of Health Examination Screening Program for Ischemic Heart Disease in Active-Duty Military Personnel in the Middle-Income Country. Front Public Health. 2021; 9:634778.
2. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011; 5:325-80. doi: 10.2147/DDDT.S14934. Epub 2011 Jun 13. PMID: 21792295; PMCID: PMC3140289.
3. Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults. Int J Cardiol. 2018; 260:196-203. PMID: 29622441 DOI: 10.1016/j.ijcard.2017.12.069.
4. Alwhaibi M, Altoaimi M, AlRuthia Y, Meraya AM, Balkhi B, Aldemerdash A, et al. Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia. Patient Prefer Adherence. 2019; 13:2111-2118. doi: 10.2147/PPA.S231873. PMID: 31853174.
5. Dakshinamurthy S, Saxena V, Kumari R, Mirza AA, Dhar M. Prevalence of hypertension and associated cardiometabolic risk factors in urban Rishikesh, Uttarakhand. J Family Med Prim Care. 2020;9(6):2931-2939. doi: 10.4103/jfmpc.jfmpc_54_20. PMID: 32984151
6. Bulelzai MA, Dubbeldam JL. Long time evolution of atherosclerotic plaques. J Theor Biol. 2012; 297:1-10. PMID: 22142625 DOI: 10.1016/j.jtbi.2011.11.023
7. Hudson SE, Feigenbaum MS, Patil N, Ding E, Ewing A, Trilk JL. Screening and socioeconomic associations of dyslipidemia in young adults. BMC Public Health. 2020 ;20(1):104. doi: 10.1186/s12889-019-8099-9. PMID: 31992243.
8. Genuth SM, Vlachos H, Brooks MM, Bantle JP, Chaitman BR, Green J, et al; BARI 2D Study Group. BARI 2D: A Reanalysis Focusing on Cardiovascular Events. Mayo Clin Proc. 2019 ;94(11):2249-2262. doi: 10.1016/j.mayocp.2019.04.015. pub 2019 Oct 4. PMID: 31590967.
9. Halle M, Berg A, Keul L, Baumstark MW. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Thromb Vasc Bioi 1996; 16:144-48. PMID: 8548415 DOI: 10.1161/01.atv.16.1.144.
10. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998 May 13;279(18):1477-82. doi: 10.1001/jama.279.18.1477. PMID: 9600484.
11. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pencells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310-20. doi: 10.1056/NEJMoa1107477. PMID: 23034020; PMCID: PMC3714101.
12. Shah D. Healthy worker effect phenomenon. Indian J Occup Environ Med 2009; 13(2): 77–79. PMID: 20386623 DOI: 10.4103/0019-5278.55123
13. Barth SK, Kang HK, Bullman T. All-Cause Mortality Among US Veterans of the Persian Gulf War: 13-Year Follow-up. Public Health Rep. 2016 ;131(6):822-830. doi: 10.1177/0033354916676278. PMID: 28123229.
14. Shpagina LA, Ermakova MA, Volkova EA, Iakovleva SA. Clinical, functional and biochemical characteristics of arterial hypertension in military men under chronic stress. Med Tr Prom Ekol. 2008;(7):24-9. Russian. PMID: 18763613.
15. Shrestha A, Ho TE, Vie LL, Labarthe DR, Scheier LM, Lester PB et al. Comparison of Cardiovascular Health Between US Army and Civilians. J Am Heart Assoc. 2019; 8(12): e009056. doi: 10.1161/JAHA.118.009056. PMID: 31164033.
16. Ratković N, Pandrc MS, Perić V, Stojanović M, Rančić N. Relationship between plasma high-sensitivity c-reactive protein and traditional cardiovascular risk factors among active-duty military personnel in Republic of Serbia. Vojnosanit Pregl. doi: 10.2298/VSP210122030R.
17. American Heart Association. Statistical Fact Sheet-Populations. International Disease Statistics. Dallas, Tex: American Heart Association. 2003.c 2003, American Heart Association. Available online at: www.americanheart.org/presenter.jhtml identifier =3001008.
18. Ministarstvo zdravlja Republike Srbije: Vodič za dijagnostikovanje i lečenje lipidskih poremećaja; 2011, Beograd.
19. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018 Oct;14(10):576-590
20. Liberale L, Montecucco F, Tardif JC, Libby P, Camici GG. Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. Eur Heart J. 2020 Aug 14;41(31):2974-2982.
21. Ray S, Kulkarni B, Sreenivas A. Prevalence of prehypertension in young military adults and its association with overweight and dyslipidaemia. Indian J Med Res. 2011;134(2):162-7. PMID: 21911967.
22. Šipetić Grujičić Sandra, Miljuš Dragan, Soldatović Ivan, Nikolić Aleksandra, Vujčić Isidora. Prehypertension and hypertension prevalence and risk factors among adult population in Republic of Serbia: A cross-sectional study. Vojnosanitetski pregled 2020 OnLine-First Issue 00, Pages: 114-114.
23. McGraw LK, Turner BS, Stotts NA, Dracup KA. A review of cardiovascular risk factors in US military personnel. J Cardiovasc Nurs. 2008;23(4):338-44. doi: 10.1097/01.JCN.0000317437. 75081.e7. PMID: 18596497.
24. Mohsen Ibrahim M. Hypertension in Developing Countries: A Major Challenge for the Future. Curr Hypertens Rep. 2018;20(5):38. doi: 10.1007/s11906-018-0839-1. PMID: 29717393.
25. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016 ;134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912. PMID: 27502908.
26. Lee JH, Seo DH, Nam MJ, Lee GH, Yang DH, Lee MJ, Choi UR, Hong S, et al. The Prevalence of Obesity and Metabolic Syndrome in the Korean Military Compared with the General Population. J Korean Med Sci. 2018;33(25): e172. doi: 10.3346/jkms.2018.33. e172. PMID: 29915523.
27. Bauduceau B, Baigts F, Bordier L, Burnat P, Ceppa F, Dumenil V, et al; Epimil group. Epidemiology of the metabolic syndrome in 2045 French military personnel (EPIMIL study). Diabetes Metab. 2005 ;31(4 Pt 1):353-9. doi: 10.1016/s1262-3636(07)70204-5. PMID: 16369197.
28. Zhang Y, Vittinghoff E, Pletcher MJ, Allen NB, Al Hazzouri Z A, Yaffe K et al. Associations of Blood Pressure and Cholesterol Levels During Young Adulthood with Later Cardiovascular Events. J Am Coll Cardiol. 2019; 74 (3) :330-341. PMID: 31319915 DOI: 10.1016/j.jacc.2019.03.529
29. Yano Y, Reis JP, Colangelo LA, Shimbo D, Viera AJ, Allen NB, et al. Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline with Cardiovascular Events Later in Life. JAMA. 2018;320(17):1774-1782. doi: 10.1001/jama.2018.13551. PMID: 30398601.
30. Lotfaliany M, Akbarpour S, Zafari N, Mansournia MA, Asgari S, Azizi F, et al.World Bank Income Group, Health Expenditure or Cardiometabolic Risk Factors? A Further Explanation of the Wide Gap in Cardiometabolic Mortality Between Worldwide Countries: An Ecological Study. Int J Endocrinol Metab. 2018;16(3): e59946. doi: 10.5812/ijem.59946. PMID: 30464769.
31. Karfo R, Kangambega FM, Kabre E, Ouedraogo P, Nacro Z, Sanogo Z, et al. Prevalence of dyslipidemia in a Burkinabe military population. African Journal of Biochemistry Research. 2020; 14(1): 1-4.
32. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011;117(18):4953-63. doi: 10.1182/blood-2010-11-316885. PMID: 21355090.
33. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258(9):1183-6. PMID: 3626001.
34. Shankar A, Wang JJ, Rochtchina E, Mitchell P. Positive association between plasma fibrinogen level and incident hypertension among men: population-based cohort study. Hypertension. 2006 ;48(6):1043-9. doi: 10.1161/01.HYP.0000245700.13817.3c. PMID: 17000922.
35. Mauriello A, Sangiorgi G, Palmieri G, Virmani R, Holmes DR Jr, Schwartz RS, et al. Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. Circulation. 2000;101(7):744-50. doi: 10.1161/01.cir.101.7.744. PMID: 10683347.
36. Maple-Brown LJ, Cunningham J, Nandi N, Hodge A, O'Dea K. Fibrinogen and associated risk factors in a high-risk population: urban Indigenous Australians, the DRUID Study. Cardiovasc Diabetol. 2010 Oct 29; 9:69. doi: 10.1186/1475-2840-9-69. PMID: 21029470; PMCID: PMC2988000.
37. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 12;294(14):1799-809. doi: 10.1001/jama.294.14.1799.
38. Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, Robbins DC, et al.; Strong Heart Study. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J. 2003 Mar;145(3):467-74. doi: 10.1067/mhj.2003.144. PMID: 12660670.
Objavljeno
2021/11/12
Rubrika
Original paper